Reader @cardiffuni. PhD @MRC_MHU @greentempleton @UniofOxford. Former Assistant Professor at @BUMedicine. My lab mission is to #beatbloodcancer.
London, England
Joined July 2019
- Tweets561
- Following1.3K
- Followers534
- Likes1.3K
Pinned Tweet
In #HeartMonth and on #WearRedDay I am pleased to announce a new PhD studentship in my lab to study and develop novel therapies to target cardiovascular disease development, application deadline March 6 for a October 2026 start, please RX:
eur03.safelinks.protection.o…
Neil Rodrigues retweeted
Menin inhibitors like revumenib and ziftomenib show high initial response rates in AML, but durability remains limited due to on-target mutations, off-target clonal evolution, and epigenetic escape. Next-generation combination strategies in the frontline setting may help minimize clonal escape.
📗 Read the full review: bit.ly/4xDEjIM
Research by Abdulrahman Alhajahjeh, Maximilian Stahl, Amer M. Zeidan and Jan Philipp Bewersdorf at @YaleMed.
Image credit: Makysm - Own work, CC0, bit.ly/4ye9k7o
#AML #Leukemia #Oncology
Neil Rodrigues retweeted
In a phase 2, randomized trial, azacitidine–venetoclax therapy led to significantly longer event-free survival than induction chemotherapy among induction-eligible patients with AML. Full PARADIGM Research Summary: nej.md/4zJr1wV
Neil Rodrigues retweeted
Beyond “non-significant” results: Why and how to test for practical equivalence | PNAS pnas.org/doi/10.1073/pnas.26…
Neil Rodrigues retweeted
👇check this article out. Great Job @kamilkranc and team
Scientists alongside Dr. Kamil R. Kranc revealed that RNA terminal uridylyl transferase enzymes 4 and 7 are druggable therapeutic targets, whose genetic deletion suppresses #AML growth, induces apoptosis, and improves the survival in #leukemic mouse models.
🔖 bit.ly/4ierwZh
Neil Rodrigues retweeted
A wonderful evening is planned at the @bloodcancer_uk Charity Ball. Organised by Nicola and support by Rhia (@RhiaStankovic and @BloodCUK_Wales ) to raise funds to support blood cancer research. Nicola has done an amazing job and we are kicking off with a very nice garden party!
Neil Rodrigues retweeted
Delighted to see our new paper out today in Science Advances! We identify TUT4/7 as therapeutic targets in AML: their deletion or inhibition compromises AML while largely sparing normal haematopoiesis. Thanks to our collaborators & @CR_UK!
science.org/doi/10.1126/scia…
Our latest paper on targeting TUT4/7 in acute myeloid leukaemia went live at 7PM, coinciding perfectly with the eclipse. A hike from work to watch and celebrate. More to follow tomorrow, thanks to everyone who contributed, @kamilkranc , @CarrollDonal and many, many others.
Neil Rodrigues retweeted
📢 BIG NEWS in ISEH's journal Experimental Hematology!!! 2 new article types specifically designed for research often difficult to publish: validated protocols, null results, phenotyping & high-value datasets. Plus fast-track review + a $650 incentive!
🔗 iseh.org/Publications/ExpHem…
📢 Experimental Hematology, the official journal of ISEH, has launched new article types and author incentives! View the latest updates and submit your next manuscript: iseh.org/Publications/ExpHem…
Neil Rodrigues retweeted
The NHGRI Myeloid Malignancy Curation Expert Panel published (Blood) a rigorous definition of GATA2 deficiency (73 clinical phenotypes, 339 patients from 16 centers in 7 countries, which will guide clinical practice). @uwsmph @wi_blood @UWCarbone @BloodCancerUtd @UWSCRMC
Neil Rodrigues retweeted
New work from our lab out today in @NatureCellBio led by @jaynathemistry!!
nature.com/articles/s41556-0…
🧵 on how clonal hematopoiesis turns the bone marrow niche into an accomplice:
Neil Rodrigues retweeted
Investigators introduce a clonal #hematopoietic stem and progenitor cell (HSPC) tracker, an in vitro framework for serially tracking clonal differentiation and fate acquisition from human HSPCs extracted from circulation.
bit.ly/45umZdH
Neil Rodrigues retweeted
Nice to see our article out: doi.org/10.1016/j.bneo.2026.… in blood Neoplasia. Proteomics of RUNX1::ETO normal human HSPC
Neil Rodrigues retweeted
Biological aging is accelerating in recent generations and it’s linked to the rise in early-onset cancers @NatureMedicine.
In UK Biobank (154k young adults):
1⃣PhenoAge “age gap” ↑ 23% s.d. in people born 1965–74 vs 1950–54
2⃣Each s.d. higher age gap → 8% higher risk of early-onset solid cancers (HR 1.08)
3⃣Strongest for lung (HR 1.57), GI/colorectal, and uterine cancers
A new integrative lens on why early-onset cancers are rising and potential prevention targets.
nature.com/articles/s41591-0…
#EarlyOnsetCancer #BiologicalAging #CancerResearch #AgingResearch #CancerPrevention #PhenoAge
Neil Rodrigues retweeted
Thrilled to announce that my review paper has been published in Aging and Disease.
This work explored how the metabolism of hematopoietic stem cells (HSCs) changes with age, and how leukemic stem cells (LSCs) exploit similar metabolic pathways to survive and resist therapy. I compared the metabolic programs — glycolysis, mitochondrial OXPHOS, and amino acid and lipid metabolism — of young HSCs, aged HSCs, and LSCs, while also addressing the clinical opportunities and challenges of targeting these vulnerabilities: rejuvenating aged HSCs without driving clonal expansion, and selectively eliminating LSCs while sparing healthy hematopoiesis.
It’s incredibly rewarding to contribute to this rapidly evolving field and to envision how a deeper understanding of stem cell metabolism could one day translate into therapies for aging-related blood disorders and leukemia.
eur04.safelinks.protection.o…
#Aging #StemCellMetabolism #Leukemia
Well done Alex, great work!
Feeling excited 🥳 to share our latest publication where we identified changes in the proteome (proteins: the workhorses of the cells) of blood cancer cells #AML expressing a common abnormality in blood cancers.
sciencedirect.com/science/ar…
Neil Rodrigues retweeted
✨ Thrilled to share our new publication in Nature.
We define an “inflammatory memory” HSC state (HSC‑iM), linking lifelong inflammatory exposure to aging and disease.
📄 Article: nature.com/articles/s41586-0…
Grateful to an incredible team and global collaborators 💚💙
Neil Rodrigues retweeted
The ramp up of cancer immunotherapy is remarkable. Now we're seeing vaccines achieve some cures or remissions in the most refractory cancers: pancreatic, melanoma, glioblastoma, renal, triple-negative breast cancer.
✓ out the new Ground Truths (link in profile)
🤖 Made with AI
Neil Rodrigues retweeted
How do lineage-biased HSC states relate to each other? check out: rdcu.be/fkASJ in @NatureCellBio
Collab with @haas_lab @ChariteBerlin BIH & MDC; Thomas Höfer & Daniel Hübschmann @DKFZ @NCT_HD @hi_stem_lab
1st authors @Esther_RCorrea @FloGrunschlager & Tamar Nizharadze
Neil Rodrigues retweeted
Review series on clonal hematopoiesis: the driver mutations.
This review explores how driver mutations shape stem cell fitness and how inflammatory progeny may promote clonal advantage and disease risk.
haematologica.org/article/vi…
Neil Rodrigues retweeted
We published a new preprint on BioRxiv. We uncovered a pyroptosis-driven stromal-immune circuit that explains why TET2 mutations progress to myeloid disease, and how to disrupt it. This work is led by @Kehan_Ren_PhD. bit.ly/42pjgwB
Neil Rodrigues retweeted
Review series on clonal hematopoiesis: from CHIP to myeloid neoplasms.
What drives progression from clonal hematopoiesis to myeloid malignancy? This review explores risk, biology, and emerging therapeutic strategies.
haematologica.org/article/vi…
